Not checkedNot checked for notices yet.
Combined anti-tumor efficacy of somatostatin fusion protein and vaccinia virus on tumor cells with high expression of somatostatin receptors
Jun Fan, Lili Deng, Ying Peng and 1 more
Scientific Reports · 2022
doi:10.1038/s41598-022-21506-8 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Somatostatin, a growth hormone-release inhibiting peptide, exerts antiproliferative and antiangiogenic effects on tumor cells. However, the short half-life of somatostatin limits its application in human therapy, and long-acting somatostatin fusion protein is also limited by its severe terminal degradation. Therefore, oncolytic virus delivery system was introduced to express somatostatin fusion protein and the anti-tumor effects of both somatostatin and oncolytic virus were combined to destroy tumor tissues. Here, a vaccinia VG9/(SST-14) 2 -HSA recombinant was constructed by replacing somatostatin fusion gene into TK locus of attenuated VG9 strain via homologous recombination. Results showed that vaccinia VG9/(SST-14) 2 -HSA possessed a combined anti-tumor effect on sstr-positive tumor cells in vitro. In the tumor burden models, BALB/c mice with complete immunity are most suitable for evaluating tumor regression and immune activation. Complete tumor regression was observed in 3 out of 10 mice treated with vaccinia VG9/TK − or VG9/(SST-14) 2 -HSA, and the survival of all mice in both groups was significantly prolonged. Besides, vaccinia VG9/(SST-14) 2 -HSA is more effective in prolonging survival than VG9/TK − . Vaccinia VG9/(SST-14) 2 -HSA exerts a combined anti-tumor efficacy including the oncolytic ability provided by the virus and the anti-tumor effect contributed by (SST-14) 2 -HSA, which is expected to become a potent therapeutic agent for cancer treatment.
Abstract licence: CC BY-NC-ND
References25
- 17.
24 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.